{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Bendamustine+%28MTD%29", "query": { "intervention": "Bendamustine (MTD)" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 11, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Bendamustine+%28MTD%29&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-24T04:48:57.165Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01871675", "title": "Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Hematologic Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoma", "Chronic Lymphocytic Leukemia", "Non-Hodgkin Lymphoma", "T-cell Lymphoma" ], "interventions": [ { "name": "IPI-145", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Bendamustine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SCRI Development Innovations, LLC", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2013-05", "completion_date": "2016-06", "has_results": false, "last_update_posted_date": "2016-07-11", "last_synced_at": "2026-09-24T04:48:57.165Z", "location_count": 4, "location_summary": "Denver, Colorado • Sarasota, Florida • Oklahoma City, Oklahoma + 1 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Oklahoma City", "state": "Oklahoma" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT01871675" }, { "nct_id": "NCT01177683", "title": "Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Bendamustine", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" }, { "name": "Filgrastim", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sherif Farag, MB, BS", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2010-07", "completion_date": "2017-12", "has_results": true, "last_update_posted_date": "2023-10-06", "last_synced_at": "2026-09-24T04:48:57.165Z", "location_count": 7, "location_summary": "Indianapolis, Indiana • Lafayette, Indiana • Wyoming, Michigan + 2 more", "locations": [ { "city": "Indianapolis", "state": "Indiana" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Lafayette", "state": "Indiana" }, { "city": "Wyoming", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT01177683" }, { "nct_id": "NCT01326702", "title": "Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Adult B Acute Lymphoblastic Leukemia", "Adult Nasal Type Extranodal NK/T-Cell Lymphoma", "Adult Solid Neoplasm", "Anaplastic Large Cell Lymphoma", "Angioimmunoblastic T-Cell Lymphoma", "Chronic Lymphocytic Leukemia", "Cutaneous B-Cell Non-Hodgkin Lymphoma", "Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue", "Hepatosplenic T-Cell Lymphoma", "Intraocular Lymphoma", "Lymphomatous Involvement of Non-Cutaneous Extranodal Site", "Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma", "Nodal Marginal Zone Lymphoma", "Recurrent Adult Acute Lymphoblastic Leukemia", "Recurrent Adult Burkitt Lymphoma", "Recurrent Adult Diffuse Large Cell Lymphoma", "Recurrent Adult Diffuse Mixed Cell Lymphoma", "Recurrent Adult Diffuse Small Cleaved Cell Lymphoma", "Recurrent Adult Grade III Lymphomatoid Granulomatosis", "Recurrent Adult Hodgkin Lymphoma", "Recurrent Adult Immunoblastic Lymphoma", "Recurrent Adult Lymphoblastic Lymphoma", "Recurrent Adult T-Cell Leukemia/Lymphoma", "Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma", "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Grade 3 Follicular Lymphoma", "Recurrent Mantle Cell Lymphoma", "Recurrent Marginal Zone Lymphoma", "Recurrent Mycosis Fungoides and Sezary Syndrome", "Recurrent Small Lymphocytic Lymphoma", "Refractory Chronic Lymphocytic Leukemia", "Refractory Hairy Cell Leukemia", "Refractory Plasma Cell Myeloma", "Small Intestinal Lymphoma", "Splenic Marginal Zone Lymphoma", "Testicular Lymphoma", "Waldenstrom Macroglobulinemia" ], "interventions": [ { "name": "Bendamustine Hydrochloride", "type": "DRUG" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Veliparib", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 43, "start_date": "2011-07", "completion_date": "2015-04", "has_results": true, "last_update_posted_date": "2019-12-16", "last_synced_at": "2026-09-24T04:48:57.165Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01326702" }, { "nct_id": "NCT04217317", "title": "CPI-613 in Combination With Bendamustine in Patients With Relapsed/Refractory T-Cell Non-Hodgkin Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Relapsed T-Cell Lymphoma", "Refractory T-Cell Lymphoma", "Non Hodgkin Lymphoma" ], "interventions": [ { "name": "CPI 613", "type": "DRUG" }, { "name": "Bendamustine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Wake Forest University Health Sciences", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2020-09-16", "completion_date": "2024-07-11", "has_results": true, "last_update_posted_date": "2025-05-02", "last_synced_at": "2026-09-24T04:48:57.165Z", "location_count": 1, "location_summary": "Winston-Salem, North Carolina", "locations": [ { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT04217317" }, { "nct_id": "NCT02954406", "title": "A Study of TAK-659 in Combination With Bendamustine (+/-Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Participants With Advanced Non-Hodgkin Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoma, Non-Hodgkin" ], "interventions": [ { "name": "TAK-659", "type": "DRUG" }, { "name": "Bendamustine", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Ibrutinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Millennium Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 43, "start_date": "2017-03-05", "completion_date": "2020-07-27", "has_results": true, "last_update_posted_date": "2022-02-18", "last_synced_at": "2026-09-24T04:48:57.165Z", "location_count": 11, "location_summary": "Tucson, Arizona • La Jolla, California • West Hollywood, California + 8 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "West Hollywood", "state": "California" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02954406" }, { "nct_id": "NCT07725406", "title": "Low-Dose TBI Plus CAR T-Cell Therapy for Relapsed/Refractory DLBCL and Multiple Myeloma", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)", "Relapsed or Refractory Multiple Myeloma (MM)" ], "interventions": [ { "name": "Lymphodepleting chemotherapy: Cyclophosphamide", "type": "DRUG" }, { "name": "Lymphodepleting chemotherapy: Bendamustine", "type": "DRUG" }, { "name": "Lymphodepleting chemotherapy: Fludarabine", "type": "DRUG" }, { "name": "Lisocabtagene Maraleucel", "type": "OTHER" }, { "name": "Axicabtagene Ciloleucel", "type": "OTHER" }, { "name": "Ciltacabtagene Autoleucel", "type": "OTHER" }, { "name": "Low-Dose Total Body Irradiation", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "OTHER", "RADIATION" ], "sponsor": "Weill Medical College of Cornell University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2026-08-01", "completion_date": "2033-08-31", "has_results": false, "last_update_posted_date": "2026-07-24", "last_synced_at": "2026-09-24T04:48:57.165Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07725406" }, { "nct_id": "NCT01594229", "title": "A Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Combination With Bendamustine/Rituximab (BR) in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-Hodgkin's Lymphoma" ], "interventions": [ { "name": "ABT-199", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Bendamustine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 60, "start_date": "2012-05-21", "completion_date": "2020-07-14", "has_results": false, "last_update_posted_date": "2021-08-02", "last_synced_at": "2026-09-24T04:48:57.165Z", "location_count": 8, "location_summary": "La Jolla, California • Los Angeles, California • Atlanta, Georgia + 5 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Augusta", "state": "Georgia" }, { "city": "Harvey", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01594229" }, { "nct_id": "NCT05451771", "title": "Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "AL Amyloidosis" ], "interventions": [ { "name": "Venetoclax Oral Tablet, 200 mg", "type": "DRUG" }, { "name": "FISH assay", "type": "DEVICE" }, { "name": "Venetoclax Oral Tablet, 400 mg", "type": "DRUG" }, { "name": "Dexamethasone Oral, 10 mg", "type": "DRUG" }, { "name": "Dexamethasone Oral, 20 mg", "type": "DRUG" }, { "name": "Daratumumab Injection", "type": "DRUG" }, { "name": "Bendamustine", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" }, { "name": "Ixazomib", "type": "DRUG" }, { "name": "Venetoclax MTD with Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "Columbia University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 53, "start_date": "2022-10-26", "completion_date": "2027-09", "has_results": false, "last_update_posted_date": "2026-07-10", "last_synced_at": "2026-09-24T04:48:57.165Z", "location_count": 5, "location_summary": "Boston, Massachusetts • Rochester, Minnesota • St Louis, Missouri + 2 more", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "St Louis", "state": "Missouri" }, { "city": "New York", "state": "New York" }, { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT05451771" }, { "nct_id": "NCT01458366", "title": "Phase I/II Study of Bendamustine in Combination With Ofatumumab, Carboplatin and Etoposide", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non-Hodgkin's Lymphoma" ], "interventions": [ { "name": "Bendamustine", "type": "DRUG" }, { "name": "Ofatumumab", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "CT Scan", "type": "PROCEDURE" }, { "name": "PET Scan", "type": "PROCEDURE" }, { "name": "Stem Cell Transplant (STC)", "type": "GENETIC" } ], "intervention_types": [ "DRUG", "PROCEDURE", "GENETIC" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 38, "start_date": "2011-11-09", "completion_date": "2020-07-23", "has_results": true, "last_update_posted_date": "2025-04-30", "last_synced_at": "2026-09-24T04:48:57.165Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01458366" }, { "nct_id": "NCT02477215", "title": "Study of Bendamustine and IXAZOMIB (MLN9708) Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "MLN9708", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Bendamustine (multiple dose levels)", "type": "DRUG" }, { "name": "Bendamustine (MTD)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Parameswaran Hari", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 38, "start_date": "2015-10-09", "completion_date": "2020-09-17", "has_results": true, "last_update_posted_date": "2020-10-22", "last_synced_at": "2026-09-24T04:48:57.165Z", "location_count": 1, "location_summary": "Milwaukee, Wisconsin", "locations": [ { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT02477215" } ] }